18d agoInvesting.com Analyst RatingsBEARISH 38Analyst
Freedom Broker downgrades Beam Global stock rating on liquidity concerns
Freedom Broker downgrades Beam Global stock rating on liquidity concerns
Archived explainer. For the current picture see today's BEAM page.
Why Is BEAM THERAPEUTICS IN (BEAM) Stock Up Today?
By the Top Tier Newswire AI Desk · August 26, 2026 at 12:05 AM ET · reviewed against 3 wire stories
BEAM THERAPEUTICS IN (BEAM) is up +9.53% in the latest session. Our newswire has captured 3 stories on BEAM across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 49/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why BEAM stock is up today
BEAM stock rose 9.53 percent to $31.03 in today’s session driven by analyst activity and expectations around clinical developments. The stock has seen renewed attention from analysts with diverging views and recent insider transactions. The stock remains unprofitable but has shown strong revenue growth.
What Happened
Freedom Broker downgraded Beam Global stock to Hold from Buy citing liquidity concerns. This downgrade was reported in two separate stories within the past 36 hours. Meanwhile H.C. Wainwright reiterates Beam Therapeutics stock rating at Buy. These conflicting analyst ratings have contributed to the stock’s volatility. Beam Therapeutics is set to present updated clinical data from its Phase 1/2 trial evaluating BEAM-302 for Alpha-1 Antitrypsin Deficiency at the ERS Congress 2026. This upcoming presentation is seen as a key milestone for the company. Additionally Prime Medicine secured a favorable arbitration ruling in the Beam Therapeutics case. This ruling could have implications for the company's legal and financial standing.
What The Data Shows
Beam Therapeutics has a market cap of $3.0 billion and remains unprofitable with an EPS TTM of -0.84. The company's revenue has grown by 158.9 percent TTM but it continues to operate at a net margin of -55.4 percent. The stock has a beta of 2.21 indicating high volatility relative to the market. The stock has traded between $16.02 and $38.26 over the past 52 weeks. Recent insider transactions include sales by Chief Medical Officer Simon Amy on 2026-06-30 and 2026-07-27 and by CEO Evans John M. on 2026-06-29. In the last 90 days insiders have sold four times totaling $12.2 million. The stock has printed 42 fresh 52-week highs on 2026-08-26.
What To Watch
The company's presentation of updated clinical data for BEAM-302 at the ERS Congress 2026 will be a key event to monitor. Investors should also watch for any shifts in analyst coverage and further insider activity.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
BEAM by the numbers
Last: $31.03Session: +9.53%7 sessions: +11.40%Coverage: 3 stories / 2 sourcesAI sentiment: 49/100 (mixed)Mkt cap: $3.0B52w: $16.02 to $38.26
The headlines behind the move
18d agoThe FlyNEUTRAL 48Analyst
Beam Global downgraded to Hold from Buy at Freedom Broker
19d agoInvesting.com Analyst RatingsBULLISH 61Analyst
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on BEAM: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier BEAM move explainers: 2026-09-09 · 2026-09-08 · 2026-08-26 · 2026-08-25 · 2026-08-20